Volume 27, Issue 1 (12-2025)
yafte 2025, 27(1): 28-40 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Cheraghi M, Hashemzadeh P, Sedighi M, Karimi A. Impact of the Valepotriate active ingredient on inflammation and the response to pain stimuli in male rats. yafte 2025; 27 (1) :28-40
URL: http://yafte.lums.ac.ir/article-1-3761-en.html
URL: http://yafte.lums.ac.ir/article-1-3761-en.html
Department of Anesthesia, Faculty of Medicine, Shahid Rahimi Hospital, Lorestan University of Medical Sciences, Khorramabad, Iran & Department of Anesthesia, Faculty of Medicine, Shahid Rahimi Hospital, Lorestan University of Medical Sciences, Khorramabad, Iran
Abstract: (322 Views)
Background: The present study was designed to evaluate the effect of Valepotriate (from Valeriana officinalis) on pain and inflammation in rats and to determine its possible analgesic and inflammatory mechanisms.
Materials and Methods: The present study was conducted with the objective of investigating the anti-inflammatory effect. To this end, 40 male rats were randomly divided into five groups. In the pain test, 56 male rats were randomly divided into seven groups (n=8 each).
Inflammation test: 1- Normal saline group, 2- Xylene group, 3- Dexamethasone group, 4 and 5- Groups that received the active ingredient Valepotriate at doses of 0.2 and 0.1 mg/kg as a single dose for each animal.
Pain test: 1- Saline group, 2- Formalin, 3- Morphine + Formalin group, 4-5- Valepotriate group (0.2 and 0.1 mg/kg) + Formalin, 6- Naloxone + Extract group (0.2 mg/kg) + Formalin, 7- Naloxone+ Morphine + Formalin group
Results: The results showed a significant decrease in pain response time at 0.2 doses of Valepotriate in acute and chronic pain phases compared to Formalin (P<0.001). Valepotriate active ingredient also exerted its inhibitory effect on xylene-induced inflammation, with the best inhibition percentage observed for 0.2 mg/kg dose and dexamethasone with extract at 0.2 mg/kg (P<0.01).
Conclusion: According to the results, Valepotriate has a relatively strong analgesic effect. It is likely that the mechanism of analgesic action of the extract is at least relatively similar to that of morphine based on opioid receptors. In the inflammation test, the extract was able to inhibit inflammation in a way similar to dexamethasone.
Materials and Methods: The present study was conducted with the objective of investigating the anti-inflammatory effect. To this end, 40 male rats were randomly divided into five groups. In the pain test, 56 male rats were randomly divided into seven groups (n=8 each).
Inflammation test: 1- Normal saline group, 2- Xylene group, 3- Dexamethasone group, 4 and 5- Groups that received the active ingredient Valepotriate at doses of 0.2 and 0.1 mg/kg as a single dose for each animal.
Pain test: 1- Saline group, 2- Formalin, 3- Morphine + Formalin group, 4-5- Valepotriate group (0.2 and 0.1 mg/kg) + Formalin, 6- Naloxone + Extract group (0.2 mg/kg) + Formalin, 7- Naloxone+ Morphine + Formalin group
Results: The results showed a significant decrease in pain response time at 0.2 doses of Valepotriate in acute and chronic pain phases compared to Formalin (P<0.001). Valepotriate active ingredient also exerted its inhibitory effect on xylene-induced inflammation, with the best inhibition percentage observed for 0.2 mg/kg dose and dexamethasone with extract at 0.2 mg/kg (P<0.01).
Conclusion: According to the results, Valepotriate has a relatively strong analgesic effect. It is likely that the mechanism of analgesic action of the extract is at least relatively similar to that of morphine based on opioid receptors. In the inflammation test, the extract was able to inhibit inflammation in a way similar to dexamethasone.
Type of Study: Research |
Subject:
فارماکولوژی
Received: 2024/08/28 | Accepted: 2025/01/12 | Published: 2025/12/31
Received: 2024/08/28 | Accepted: 2025/01/12 | Published: 2025/12/31
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
